Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2023 Earnings Call Transcript August 10, 2023 Daré Bioscience, Inc. reports earnings inline with expectations. Reported EPS is $-0.1 EPS, expectations were $-0.1. Operator: Welcome to the conference hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended June 30, 2023, and to provide a General […]
Top in women's health: Capsule for vulvovaginal atrophy; breaking down US birth data healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT Webinar to include presentations by Daré management and key opinion leaders in reproductive and sexual medicine SAN DIEGO, July .
Treatment with a vaginal tamoxifen capsule in postmenopausal women with moderate to severe vulvovaginal atrophy was safe with minimal drug exposure, researchers reported in a phase 1/2 clinical study.The vaginal tamoxifen capsule, DARE-VVA1 (Daré Bioscience), is a soft gelatin capsule containing tamoxifen to treat vulvovaginal atrophy without hormones in postmenopausal women.